Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

09:00am - American Society of Clinical Oncology Meeting - Abstract No #4507

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.09 USD

Average target price

53.19 USD

Spread / Average Target

+29.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-18.22%	83.29B
ELI LILLY AND COMPANY	+42.79%	739B
NOVO NORDISK A/S	+32.34%	598B
JOHNSON & JOHNSON	-5.57%	353B
MERCK & CO., INC.	+17.75%	318B
ABBVIE INC.	+3.76%	285B
ASTRAZENECA PLC	+16.47%	240B
NOVARTIS AG	+9.26%	210B
ROCHE HOLDING AG	-5.07%	206B
AMGEN INC.	+6.74%	164B

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 04:03:13 2024-06-03 pm EDT			5-day change	1st Jan Change
42.02 ^USD	+2.28%		+3.28%	-18.50%

07:39pm	Bristol-Myers Squibb Says Breyanzi Studies Show 'Meaningful' Outcomes Across B-cell Malignancies	MT
02:58pm	Bristol Myers: presents advances in lung cancer	CF

Bristol-Myers Squibb Says Breyanzi Studies Show 'Meaningful' Outcomes Across B-cell Malignancies	01:39pm	MT
Bristol Myers: presents advances in lung cancer	08:58am	CF
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	Jun. 02	RE
GSK blood cancer drug nearly halves risk of death in late-stage trial	Jun. 02	RE
Bristol Myers Squibb Announces Results from the Phase 3 KRYSTAL-12 Study Evaluating KRAZATI®?	Jun. 01	CI
Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma	May. 30	MT
Bristol Myers: FDA approval for Breyanzi	May. 30	CF
US FDA allows use of Bristol's cell therapy for rare blood cancer	May. 30	RE
U.S. Food and Drug Administration Approves Bristol Myers Squibb?s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma	May. 30	CI
Bristol Myers Squibb’s Urothelial Carcinoma Combo Drug Gets EU Commission Approval	May. 29	MT
Bristol-Myers Squibb Gains EU Approval for Opdivo Combination Therapy for Urothelial Cancer	May. 29	MT
Bristol Myers: new EC approval for Opdivo	May. 29	CF
Bristol Myers Squibb Receives European Commission Approval for Opdivo in Combination with Cisplatin and Gemcitabine	May. 29	CI
Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License	May. 28	MT
Bristol Myers: will present data on schizophrenia	May. 27	CF
Bristol Myers: presents over 130 studies at ASCO	May. 27	CF
Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment	May. 23	MT
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million	May. 22	RE
Bristol-Myers Squibb Announces Strategies to Improve Access to Medicines	May. 22	MT
Bristol Myers: 10-year strategy for poor countries	May. 22	CF
Bristol-Myers Squibb Invests in NeoPhore	May. 22	MT
Neophore Limited announced that it has received funding from a group of investors	May. 21	CI
Bristol Myers: national schizophrenia campaign	May. 21	CF
Bristol-Myers Squibb Says US FDA Reassigns Action Date Subcutaneous Nivolumab	May. 21	MT
Bristol Myers: deadline set for subcutaneous Opdivo	May. 21	CF